Business
First Day of Dealings on AIM
First Day of Dealings on AIM.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 6497A\n Arecor Therapeutics PLC\n 03 June 2021\n \n \n \n THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE SAME WOULD BE UNLAWFUL.\n \n \n \n \n \n \n \n Arecor Therapeutics plc\n \n \n (\"Arecor\", the \"Company\" or the \"Group\")\n \n \n \n \n \n First Day of Dealings on AIM \n \n \n \n \n \n \n \n \n \n Cambridge, UK.,\n \n 3 June 2021: Arecor Therapeutics plc, a globally focused biopharmaceutical company that is targeting improving patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products, is pleased to announce the admission of its Ordinary Shares to trading on AIM, a market operated by London Stock Exchange plc (\"Admission\"). \n \n \n \n \n \n Admission follows a successful oversubscribed placing by Panmure Gordon (UK) Limited (\"Panmure Gordon\"), raising gross proceeds of £20.0 million at a price of 226 pence per share. On Admission the Company will have a market capitalisation of approximately £62.5 million. \n \n \n \n \n \n Trading of shares will begin at 8.00 am today under the ticker symbol \"AREC\" and the ISIN number GB00BMWLM973.\n \n \n \n \n \n \n Sarah Howell, Chief Executive Officer of Arecor, said: \n \n \n \"Today represents an important milestone for Arecor and we are very pleased to be listing on AIM. This IPO will allow us to continue to grow the business through the development of our own proprietary diabetes and specialty hospital products whilst creating further value through our technology licensing partnerships. We were delighted by the support and interest we received during this transaction which is testament to the potential of our innovative proprietary formulation technology platform, Arestat™. I would like to take this opportunity to thank our new and existing shareholders for their support and we are looking forward to embarking on this next exciting chapter in the Company's development.\"\n \n \n \n \n \n \n \n \n \n Placing Statistics\n \n \n \n \n \n \n \n \n Placing Price ...